Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

A. Punnoose, Elizabeth; D. Leverson, Joel; Peale, Franklin; R. Boghaert, Erwin; D. Belmont, Lisa; Tan, Nguyen; Young, A.; J. Mitten, Michael; Ingalla, Ellen; C. Darbonne, Walter; Oleksijew, Anatol; Tapang, Paul; Peng, Yue; Oeh, Jason; Lee, Leslie; Maïga, Sophie; J. Fairbrother, Wayne; Amiot, Martine; J. Souers, Andrew; Sampath, Deepak

doi:10.1158/1535-7163.mct-15-0730

Public

Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

Published in Molecular Cancer Therapeutics • Mar 3, 2016

Authors:

Elizabeth A. Punnoose

Joel D. Leverson

Franklin Peale

Abstract

BCL-2 family proteins dictate survival of human multiple myeloma cells, making them attractive drug targets. Indeed, multiple myeloma cells are sensitive to antagonists that selectively target prosurvival proteins such as BCL-2/BCL-XL (ABT-737 and ABT-263/navitoclax) or BCL-2 only (ABT-199/GDC-0199/...

Subject

Venetoclax

Multiple myeloma

Bortezomib

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!